For healthcare professionals only

Letters Views on lipid lowering

JUPITER seems to be bypassed

BMJ 2010; 341 doi: (Published 19 October 2010) Cite this as: BMJ 2010;341:c5835
  1. Scott W Murray, specialist registrar in cardiology1
  1. 1Aintree University Hospital NHS Foundation Trust, Liverpool, UK
  1. scottmurray{at}

Krumholz and Hayward’s analysis of lipid lowering therapy refreshingly emphasised the need to focus on hard clinical end points and not biomarkers.1 However, despite mentioning some recent landmark trials, they did not give an opinion on the recent controversy surrounding JUPITER, the large, double blind, placebo controlled trial of rosuvastatin treatment.2

This trial enrolled 17 802 …

View Full Text

Log in

Log in through your institution


* For online subscription